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Abstract
We have reported that HT29 colon cancer cells, which
( )are radiosensitized by fluorodeoxyuridine FdUrd , ex-
hibit a greater increase in cyclin E–dependent kinase
activity and progress further into S phase in the pres-
ence of FdUrd than do SW620 colon cancer cells, which
(are only minimally sensitized by this drug Cancer Res
)56: 3203, 1996 . Although these findings suggested that
the ability to progress into S phase in the presence of
FdUrd permits cells to be radiosensitized, we wished to
test this hypothesis by attempting to drive SW620 hu-
man colon cells into S phase by transducing them with
the HPV16-E7 gene. Two-parameter flow cytometry
showed that E7-transduced cells progressed through S
phase after radiation and FdUrd treatment more rapidly
than SW620 parental cells. We found that E7-trans-
duced SW620 cells were significantly radiosensitized
( )by FdUrd 100 nmol/L, 14 hours with an enhancement
ratio for 2 clones of 1.47"0.03 and 1.51"0.14, com-
pared with 1.24"0.04 in SW620 parental cells. These
data strongly support the hypothesis that dysregulation
of S-phase progression is an important factor in
FdUrd-mediated radiosensitization.
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Introduction
The combination of fluoropyrimidines and radiation has been
demonstrated in randomized trials to improve the survival of
patients with colorectal cancer, esophageal cancer, pancre-
atic cancer, and head and neck cancers and is widely used
[ ]in the treatment of other malignancies 1 , yet the mecha-
nism of interaction is imperfectly understood. The two chief
( )fluoropyrimidines in clinical practice are 5-fluorouracil FUra
( )and fluorodeoxyuridine FdUrd , the former of which has
both DNA and RNA-directed effects and the latter only DNA
[ ]directed effects at clinically relevant concentrations 2,3 .
We have hypothesized that FdUrd-mediated radiosensitiza-
tion depends on the ability of cells to progress into and
[ ]through S phase on a damaged template 4 . By using HT29
and SW620 human colon cancer cells, we have found that
radiosensitization correlates with progression into S phase
[ ] [ ]5 and elevation of cyclin E–dependent kinase activity 6 in
the presence of drug and that sensitization is blocked by
treatment with the DNA alpha polymerase inhibitor aphidi-
[ ]colin administered just before radiation 5 . Radiosensitiza-
tion does not appear to be due strictly to redistribution of
cells into a sensitive phase of the cell cycle, because the
mid–S-phase fraction of FdUrd-treated cells is radiosensi-
tized, whereas this same fraction of drug-naive cells is
[ ]relatively resistant compared to asynchronous cells 5 . Fur-
thermore, aphidicolin, under conditions that inhibit radiosen-
sitization, has no effect on FdUrd-mediated cell cycle
[ ]changes 4 .
Although these studies suggest that progression into S
phase in the presence of drug is crucial in producing ra-
diosensitization, the experiments described were carried out
(with two different cell lines HT29 cells, which are radiosen-
)sitized, and SW620 cells, which are not . To test our hypoth-
( )esis more directly, we compared SW620 parental cells to
SW620 cells infected with a retroviral construct carrying the
HPV-16 gene E7. E7 has been shown to bind to Rb,
leading to its ubiquitination and degradation, thus releasing
transcription factors in the E2F family and facilitating unreg-
[ ]ulated transition from G1 to S 7,8 . Consistent with this
model, we found that SW620 cells transduced with E7
progressed into S phase after treatment with FdUrd and
radiation more avidly than SW620 parental cells and that, in
contrast to SW620 parental cells, E7-transduced cells were
radiosensitized. These findings suggest that dysregulation
of and progression in S phase in response to fluoropyrim-
idines may be required to produce increased radiation sen-
sitivity.
Materials and Methods
Cell Culture
Cells were cultured in RPMI with 10% bovine calf serum,
[ ]as described previously 9 . The concentration of thymidine
in the medium was approximately 0.2 mmol/L. Cells were
released from the flasks with phosphate buffered saline
( )PBS containing 0.03% trypsin and 0.27 mmol/L EDTA and
plated into 100-mm culture dishes 2 days before experi-
ments. This procedure produced exponentially growing cells
at the time of drug addition. Incubations with drugs were
performed in media containing 10% dialyzed calf serum.
Cells were checked for mycoplasma every 3 months.
Construction of E7-Transduced Cells
SW620 cells were infected with a retrovirus carrying the
HPV16-E7 gene and a neomycin resistance marker. The
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Table 1. Radiation Sensitivity of SW620 Parental and HPV16-E7–Transduced SW620 Cells.
U y1 y 2 †( ) ( ) ( )Cell Line Mean Inactivation Dose Gy Enhancement ratio Alpha Gy Beta Gy Surviving Fraction
Untreated FdUrd Untreated FdUrd Untreated FdUrd FdUrd
SW620par 1.67" 0.09 1.44" 0.06 1.24" 0.04 0.51" 0.06 0.49" 0.09 0.04" 0.01 0.09" 0.01 0.83" 0.07
SW620E7.8 1.82" 0.06 1.17" 0.05 1.47" 0.03 0.42" 0.05 0.66" 0.05 0.06" 0.01 0.10" 0.01 0.91" 0.10
SW620E7.9 1.72" 0.08 1.25" 0.15 1.51" 0.14 0.49" 0.05 0.66" 0.11 0.05" 0.01 0.10" 0.02 0.95" 0.08
Data are expressed as mean"SEM of at least 3 experiments.
UEnhancement ratio is calculated as the ratio of the radiation dose under control conditions divided by the radiation dose under drug-treated conditions,
which reduced the surviving fraction to 1%.
†Data are expressed as surviving fraction of FdUrd-treated cells relative to that of untreated cells.
cells were incubated with the viral supernatant from PA16
E7-producing cells, after which transduced cells were se-
lected with 1 mg/mL G418.
Cell Survival Assay
[ ]Cell survival was assessed by clonogenic assay 5 .
Radiation survival data from FdUrd treated cells were cor-
rected for plating efficiency by using an unirradiated plate
treated with drug under the same conditions. Each experi-
ment was plated in triplicate. Cell survival curves were fitted
by using the linear-quadratic equation, and the mean inacti-
( )vation dose the area under cell survival curve was calcu-
[ ]lated by using the method of Fertil and colleagues 10 . The
cell survival enhancement ratio was calculated as the ratio
of the radiation dose under control conditions divided by the
radiation dose under drug-treated conditions which reduced
( )the surviving fraction to 1% Table 1 .
Irradiation Conditions
60 (Cell irradiations were performed with a Co unit Ther-
)atron AECL, Kanata, Ontario, Canada at 1 to 2 Gy/minute.
Dosimetry was carried out by using an ionization chamber
connected to an electrometer system directly traceable to a
National Institute of Standards and Technology calibration.
Flow Cytometry
Cells were trypsinized, washed in PBS, fixed by drop-wise
addition of 2.5 volumes of cold 70% ethanol, and stored at
48C until the day of analysis. They were then washed with
PBS, suspended in propidium iodide, and analyzed on an
( )EPICS C flow cytometer Coulter Electronics, Hialeah, FL .
Salmon red blood cells were used as an internal standard.
To monitor S-phase progression, cells were treated with
FdUrd and/or radiation and either processed immediately or
( )returned to thymidine 3 mmol/L containing media for vary-
ing times. During the last 15 minutes of incubation, cells
( )were treated with 30 mmol/L bromodeoxyuridine BrdUrd .
They were then processed for immunoassay with a first
( [ ])antibody mouse anti-BrdUrd Pharmingen, San Diego, CA ,
(followed by FITC-goat-anti-mouse IgG Sigma, St. Louis,
) [ ]MO 11,12 .
Immunoblotting
[ ]Protein levels were determined by immunoblotting 6 .
Cells were trypsinized, counted, and lysed with detergent
buffer containing protease inhibitors. Aliquots of the lysates
were electrophoresed by using standard SDS-PAGE tech-
(niques. After equilibrating the gel with Towbin buffer Tris /
)glycine/methanol , the proteins were transferred to Immo-
(bilon paper by using a Hoeffer TE42 Transphor unit San
)Francisco, CA . The blot was then washed in blocking buffer
and wash buffer, incubated with the primary antibody,
washed, incubated with anti-IgG2 coupled to horseradish
peroxidase, and developed with a chemiluminescence de-
( )tection system Pierce, Rockford, IL . E7, cyclin A, cyclin E,
and cdk 2 antibodies were obtained from Pharmingen.
Thymidylate Synthase Assay
( )The activity of thymidylate synthase TS in cell extracts
from control or FdUrd-treated cells was determined by mea-
suring the conversion of 3H dUMP to dTMP with the release
3 [ ]of H O by using the method of Maley et al 13 . Cells were2
washed with cold PBS, scraped, and sonicated. An aliquot
of the extract was then incubated at 378C for 30 minutes
with 3H dUMP in the presence of 50 mmol/L Tris, 5 mmol/L
MgCl , 50 mmol/L NaF, 10 mmol/L dUMP, and 1 mmol/L2
reduced folate. The reaction mixture was then treated with
activated charcoal suspended in 4% perchloric acid and
centrifuged. The supernatant, containing 3H O produced by2
TS, was processed for liquid scintillation counting.
Cyclin H1 Kinase Assay
Cyclin E– and A–dependent kinase activities were mea-
sured by immunoprecipitating cell extracts of equal protein
content with the appropriate cyclin antibody and binding of
[ ]the precipitate to Protein A Sepharose beads 14 . After
washing, the bead-antibody-cyclin complex was reacted with
histone H1, ATP, and 32P ATP. After incubation, the mixture
was boiled in Laemmli buffer and resolved on a 12%
SDS-PAGE gel. The gel was stained with Comassie blue to
assess loading, washed to remove unbound isotope, and
dried. The amount of kinase activity was determined by
autoradiography, and quantitative analysis was performed
(by phosphor imaging of the dried gels Molecular Dynamics,
)Sunnyvale, CA .
Table 2. Thymidylate Synthase Activity in Parental and HPV16 -E7 –
Transduced SW620 Cells Treated with FdUrd.
6( )Cell Line Thymidylate Synthase Activity cpm/10 cells/min
Untreated 100 nmol/L FdUrd
SW620par 16.99"4.4 0.91"0.15
SW620E7.8 26.64"10.4 1.09"0.08
SW620E7.9 26.91"9.7 1.20"0.14
Data are expressed as mean"SEM of at least 3 experiments.
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Figure 1. Effect of FdUrd on the radiation sensitivity of SW620 cells and
E7-containing clones. SW620E7.8, SW620E7.9, and SW620 parental
cells were exposed to 100 nmol/L of FdUrd for 14 hours. They were
then irradiated and assessed for cell survival with a clonogenic assay.
Results of a single experiment using 100 nmol/L FdUrd are shown.
Statistical Analysis
Unless otherwise indicated, data are presented as the
mean" the standard error of at least 3 independent experi-
ments. Two means were compared by using the Student t
test for either paired samples or pooled variances, and 3
means were compared by using the F-test for multiple
means. Statistical significance is defined at the level of
( )P- .05 two-tailed .
Results
To test our hypothesis that forcing SW620 cells into S
phase in the presence of FdUrd would cause them to
become radiosensitized, we needed to construct and char-
acterize SW620 cells transduced with HPV16-E7. SW620
cells were infected with retrovirus and were selected by
culturing in neomycin, as described in Materials and Meth-
ods. Neomycin-resistant clones were screened using im-
( )munoblotting for the presence of E7 data not shown . Two
( )clones SW620E7.8 and SW620E7.9 were chosen for com-
parison to SW620 cells. E7-transduced cells have approxi-
mately the same population doubling time as parental cells
(15.2"2.8, 15.6"2.8, and 17.9"3.5 h for SW620,
)SW620E7.8 and SW620E7.9, respectively . Because it has
been reported that Rb inactivation leads to greater TS
[ ]activity and, potentially, fluoropyrimidine resistance 15 , we
assessed the TS activity of our E7-transduced cells. We
found that E7-transduced cells did show greater TS activity
( )than the SW620 parental cells Table 2 . However, under
the conditions that were used to assess radiosensitization
( )exposure to 100-1000 nmol/L FdUrd for 14 hours , TS
activity was greater than 95% inhibited, and only modest
(and similar cytotoxicity was produced in all cell lines Tables
)1 and 2 . Thus, it was possible to use this model system to
assess the effect of E7 transduction on FdUrd-mediated
radiosensitization.
In confirmation of our hypothesis, we found that, in con-
trast to SW620 parental cells, SW620E7.8 and SW620E7.9
(clones were significantly radiosensitized by FdUrd Figure
) ( )1, Table 1 . FdUrd 100 nmol/L for 14 hours produced a
radiation enhancement as calculated by determining the
Figure 2. S-phase progression after treatment with FdUrd and radiation. SW620 parental cells and SW620E7.8 cells were exposed to 100 nmol /L
FdUrd for 14 hours, followed by 5 Gy of irradiation. They were then exposed to BrdUrd, as described in Materials and Methods, and assessed at the
( )indicated times time 0 being immediately after radiation for S-phase progression by 2-parameter flow cytometry. BrdUrd is a thymidine analogue and is
incorporated into DNA during S phase; thus measurement of its presence in DNA indicates whether or not cells are actively synthesizing DNA at the
time of its presence. Increasing DNA content indicates progression of cells from G1 through S phase to G2 phase.
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Figure 3. Influence of FdUrd on cyclin levels and on cyclin-dependent kinase activity. SW620 parental and E7-transduced cells were treated with FdUrd
( ) ( )as described in Figure 2. At the end of the exposure period, they were assessed for a content of cyclins A and E by immunoblotting and b
cyclin-dependent kinase activity by the H1 kinase assay, as described in Materials and Methods.
ratio of the radiation dose under control conditions divided
by the radiation dose under drug-treated conditions, which
(reduced the surviving fraction to 1% 1.47"0.03, 1.51"
0.14, and 1.24"0.04 in SW620E7.8, SW620E7.9, and
)SW620 parental cells, respectively; P- .05 . Radiosensiti-
zation produced by FdUrd results from a change in the
(low-dose shoulder region of the cell curve the alpha com-
)ponent in the linear quadratic equation , which is consistent
[ ]with our previous work in HT29 cells 4 .
We had hypothesized that the E7-transduced clones
were more radiosensitized by FdUrd because they pro-
gressed more efficiently through S phase. To assess this,
(we exposed SW620 and SW620E7.8 cells to FdUrd 100
) ( )nmol/L for 14 hours and radiation 5 Gy under the same
conditions as used for the clonogenicity assays described
earlier, except that cells were monitored for cell cycle pro-
gression. We found that SW620E7.8 cells progressed more
rapidly through S phase after drug and radiation treatment
than SW620 cells. Eight hours after radiation, SW620E7.8
cells had entered G2, whereas the majority of SW620 cells
( )were still in S phase Figure 2 . Control experiments were
also performed with untreated cells and cells treated with
FdUrd alone. Compared with the combination of FdUrd and
radiation, radiation alone produced little change in the rate
of S-phase progression, but did cause the expected block in
G2. S-phase progression after treatment with FdUrd alone
produced results similar to the combination of FdUrd and
radiation, although there was no evidence of a G2 block.
We then wished to determine if S-phase progression in
E7-transduced cells followed the same pattern of cyclin
activation as in parental cells. We found that both the
SW620 parental cells and E7 clones showed a substantial
(elevation of cyclin E levels when treated with FdUrd 100
)nmol/L for 14 hours without evidencing a significant in-
(crease in cyclin E–dependent kinase activity ratio of FdUrd
treatment to control for SW620 parental, SW620E7.8, and
SW620E7.9s1.2"0.1, 1.0"0.2, and 1.4"0.2, respec-
) ( )tively Figure 3 . These findings are consistent with those
of other investigators demonstrating that E7 expression
permits S-phase progression through mechanisms both dis-
tal to cyclin E kinase–dependent phosphorylation of Rb and
[ ]independent of the normal cell cycle machinery 16,17 . In
addition, FdUrd treatment did not change cyclin A levels in
parental cells or E7-transduced clones. However, SW620
parental cells tended to show increased cyclin A–dependent
kinase activity, whereas the E7-expressing clones tended to
(show decreased kinase activity after FdUrd treatment ratio
of kinase activity after FdUrd treatment compared with con-
trol for SW620 parental, SW620E7.8, and SW620E7.9s1.5
) ("0.3, 0.6"0.1, and 0.7"0.1, respectively; Ps .06 Fig-
)ure 3 . The decrease in cyclin A–dependent kinase activity
in the E7-transduced cells is not due to a decrease in cdk2
( )levels, as assessed by Western analysis data not shown .
Discussion
We have shown that SW620 human colon cancer cells,
whose radiation sensitivity is minimally affected by FdUrd
treatment, become significantly radiosensitized by FdUrd
when transduced with HPV16-E7. Radiosensitization is re-
(flected in the low-dose region of the cell survival curve an
increase in the alpha component of the linear quadratic
)equation suggesting that it occurs at radiation doses typi-
( )cally used in the clinic approximately 2 Gy . This increased
radiation sensitivity is associated with more efficient pro-
gression through S phase after FdUrd and radiation treat-
ment. E7-transduced cells do not rely on the normal mecha-
nisms of cyclin elevation and cyclin-dependent kinase activ-
( )ity to progress in S phase after drug treatment see below ,
which suggests that cell cycle progression itself in the
presence of FdUrd and radiation is crucial rather than the
activation of a particular combination of cyclin or cyclin-de-
pendent kinase activities.
It is of interest to contrast the cell cycle arrest produced
by FdUrd with p53-mediated G1 arrest. A variety of insults,
[ ] [ ]including radiation 18,19 , and fluoropyrimidines 20,21 can
increase levels of p53 and cause cells to arrest in G1.
Arrest is mediated by p53-dependent activation of p21,
which inhibits the activation of cyclin D– and E–dependent
kinases. This inhibition represents a point of similarity be-
tween FdUrd-mediated radiosensitization and G1 arrest in
that we have found that cyclin E–dependent kinase activity
is not elevated by FdUrd treatment in SW620 cells despite
the large rise in cyclin E protein levels. However, HT29
cells, SW620 cells, and normal skin fibroblasts treated with
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(FdUrd under radiosensitizing conditions 100 nmol/L for 14
)hours cells actually arrest in very early S phase, based on
the findings that these cells have essentially G1 DNA con-
( )tent and that a brief 15-minute exposure to BrdUrd results
[ ]in incorporation in greater than 90% of the cells 6 . In
[ ]addition, although TS inhibitors such as ZD1694 22,23 and
[ ]FUra 24,25 cause increased levels of p53, this increase
appears to occur as cells attempt to enter S phase, i.e.,
after the G1 checkpoint. Furthermore, if cells are allowed to
progress into S phase in the presence of FdUrd, p53 activa-
(tion induced by using cells containing a temperature-sensi-
)tive p53 expression system has no effect on radiosensitiza-
[ ]tion 26 . Finally, the arrest of SW620 cells after FdUrd
treatment can be distinguished from p53-mediated arrest
( )because SW620 cells are mutant in p53 his273 and show
an increase in neither p21 nor p27 after FdUrd treatment
( )Davis and Lawrence, unpublished observations . We feel
these data are consistent with the findings that FdUrd pro-
duces a p53-independent cell cycle arrest in early S phase
and that cyclin E dependent–kinase activity stimulates very
early events involved in S-phase progression. E7 expres-
sion disrupts cell cycle controls downstream to the influence
( )of cyclin E by complexing with Rb and, as we observed,
would not be anticipated to affect cyclin E–dependent ki-
nase activity. This lack of influence of the level of cyclins
and cyclin dependent kinases in E7-transduced cells has
[ ]been described in E7-transduced RKO cells as well 27 .
We found that E7-transduced cells showed an increase
in TS activity, which is consistent with the observed in-
crease in TS activity in cells lacking Rb. This increase has
been attributed to an overall stimulation of S-phase en-
zymes. The high concentrations of FdUrd that we used
inhibited TS in all clones, so that the difference in TS activity
did not appear to influence the results of these experiments.
We also found a decrease in cyclin A–dependent kinase
activity in E7-transduced cells treated with FdUrd. E7-trans-
duced cells do not require the cyclin-dependent kinase
activities to release E2F, and a similar decrease in cyclin
A–dependent kinase activity has been noted in E7-trans-
duced RKO human colon cancer cells treated with actino-
[ ]mycin D 28 .
Our data suggest that it may be worthwhile to investigate
the stimulation of S-phase progression for therapeutic bene-
fit. The potential of this approach has already been sug-
gested by the observation that stimulation of S-phase pro-
gression, produced by the PI-3 kinase inhibitor 7-hydroxy-
[ ]staurosporine, increased the cytotoxicity of cisplatin 29 .
This concept could be applicable to increasing radiation
sensitivity as well. The influence of S-phase progression on
radiation sensitivity observed in ataxia telangiectasia has
[ ]been associated with radiation-resistant DNA synthesis 30
which is now known to be caused by a defect in the ATM
[ ]gene 31 . In addition, the PI-3 kinase inhibitor Wortmannin
[ ]has been shown to increase radiation sensitivity 32 . Given
that many cancer cells have lost normal regulation of S
phase, it may be possible to achieve more selective toxicity
against cancer cells by using approaches that target S-phase
progression.
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